Lobo Technologies Shares Jump 32% on Improved H1 Loss and Sales Growth
Lobo Technologies saw a 32% premarket gain after reporting a reduced first-half loss and higher revenue, leading a volatile session for small-cap stocks.
Key points
- Lobo Technologies shares rose 32.4% to $0.70 in premarket trading after reporting a reduced H1 loss of 7 cents per share.
- Company sales increased to $14.587 million in the first half, up from $12.091 million in the same period the previous year.
- Other premarket movers included Greenland Energy Co, which gained 138.3%, and Research Frontiers Inc, which fell 27.5%.
Lobo Technologies Ltd shares surged 32.4% to $0.70 in premarket trading following the release of its first-half financial results. The company reported a narrowing net loss of 7 cents per share, a significant improvement from the 28-cent loss recorded in the same period last year. This reduction in losses coincided with a rise in sales to $14.587 million, up from $12.091 million in the prior year, driving the sharp upward movement in the stock's price.
Improved First Half Financial Performance
The company’s operational metrics showed a clear trajectory toward better profitability, as evidenced by the significant decrease in per-share losses. According to data cited by benzinga.com, the revenue growth of approximately 20.6% was the primary catalyst for the investor sentiment shift. While the company remains in the red, the direction of the financials suggests that cost controls or revenue mix changes are beginning to offset the heavy burn rates typical of early-stage electric vehicle manufacturers.
Mixed Premarket Moves Across Sectors
Lobo’s rally occurred against a backdrop of mixed trading for other small-cap stocks. Greenland Energy Co posted the day’s largest gain, climbing 138.3% to $2.86, while Black Titan Corp rose 95.2% to $0.71. Conversely, Research Frontiers Inc dropped 27.5% to $0.47, reversing a large previous day gain. SmartKem Inc fell 24.7% to $1.65 following a preliminary prospectus filing for the resale of up to 15.1 million common shares, a move that often pressures stock prices due to potential dilution.
Biopharma names also saw volatile action. Cue Biopharma Inc rose 29.8% to $48.11 after announcing positive topline results from its CUE-221 Phase 2 study in chronic spontaneous urticaria. In contrast, Delixy Holdings Ltd declined 22% to $0.67, a move that followed its recent announcement of a 1-for-5 reverse stock split. Telix Pharmaceuticals fell 7.9% to $11.60 after signing a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE. These moves highlight the sensitivity of small-cap equities to specific corporate announcements and regulatory filings.
Notable Decliners In Pre Market
Several other stocks experienced significant premarket declines, reflecting broad volatility in the sector. IM Cannabis Corp dropped 24.1% to $3.21 after a 143% jump on Friday, suggesting profit-taking. Quanome Technologies, Inc declined 19.3% to $0.45, and Allarity Therapeutics Inc fell 17.3% to $1.00. NextNRG Inc and Aligos Therapeutics Inc also posted double-digit losses, falling 15.8% and 15.1% respectively. The divergence between Lobo’s gain and these declines illustrates the lack of a uniform market direction, with individual company news dominating price action.
